Detalhe da pesquisa
1.
A phase 1 study of romidepsin and pralatrexate reveals marked activity in relapsed and refractory T-cell lymphoma.
Blood
; 131(4): 397-407, 2018 01 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-29141948
2.
Brentuximab vedotin and bendamustine produce high complete response rates in patients with chemotherapy refractory Hodgkin lymphoma.
Br J Haematol
; 180(5): 757-760, 2018 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-27984643
3.
Combination of ibrutinib and chemotherapy produced a durable remission in multiply relapsed diffuse large B-cell lymphoma leg type with mutant MYD88 and wildtype CD79.
Haematologica
; 102(7): e275-e277, 2017 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-28341730
4.
High rate of complete responses to immune checkpoint inhibitors in patients with relapsed or refractory Hodgkin lymphoma previously exposed to epigenetic therapy.
J Hematol Oncol
; 9(1): 132, 2016 11 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-27899158